Adrijana Vinter, PhD, MBA
, became Managing Director in Jan 2017. Obtained her PhD in Chemistry at the University of Zagreb in the field of new macrolide antibiotics. She started her career in PLIVA 16 years ago working initially as a scientist and then obtained an MBA at Cotrugli Business School, Croatia before moving to Business Development on the creation of Fidelta. She has successfully engineered and overseen the development of the Fidelta revenue stream resulting in significant year on year growth.
Head of Finance
Ms. Gradečak Galović is a Chartered Management Accountant and holds a Bachelor Degree in business administration (University of Zagreb). She joined GSK in 2007 as Finance analyst prior to becoming Finance Manager DPU Macrolide in 2009. Ms Gradečak Galović has held her current position since 2010. Prior to joining GSK, she spent five years as a Management Accountant in Unilever Croatia.
Head of Translational Research and Alliances
Dr. Vesna Eraković Haber holds a medical degree and a PhD in biomedical sciences and pharmacology (Medical School, University of Rijeka, Croatia), as well as an MBA degree (IEDC Bled School of Management, Slovenia). She has been working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos for the last 18 years holding several leading R&D positions including Director of Drug Discovery and Director of Research in PLIVA, Director of Biology in GSK and VP Biology in Galapagos. Her work, focused mainly on anti-infective and anti-inflammatory research has contributed to the progression of several drug discovery projects and resulted in more than 50 peer reviewed publications. She is Professor at the Department of Pharmacology, Medical School and Professor at the Department of Biotechnology, University of Rijeka.
Head of Chemistry
Gordon Saxty did his Masters in Medicinal Chemistry at the University of Manchester (UMIST) where, as part of this degree, he also worked at Sanofi-Aventis (formally RPR). He then went on to do a PhD in Synthetic Organic Chemistry at Imperial College, London under the supervision of Professor Donald Craig. He previously held the position of Associate Director, Medicinal Chemistry at Astex Pharmaceuticals in Cambridge, UK where he worked for just over 12 years on Fragment Based Drug Discovery (FBDD) programmes. Several of these have progressed into clinical trials as potential new drugs to treat cancer. He is also an inventor on over 25 published patents and is an author on one of the most accessed Journal of Medicinal Chemistry articles from 2007, on FBDD of PKB/Akt inhibitors. As an individual who has made a significant contribution to industry in the early stages of their career, he was recently recognised with the Royal Society of Chemistry Young Industrialist of the Year Award 2013.
Head of DMPK
Dr. Jasna Padovan obtained a degree in biochemistry from the University of Colorado, was trained in PK/PD within the Leiden/Amsterdam Centre for Drug Research and obtained her PhD in Analytical Chemistry from the University of Zagreb. Jasna started her industrial career in 1998 working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos mainly in the areas of anti-infectives, anti-fungals, inflammation and CNS, holding the position of head of DMPK. During her career she has worked on projects which have delivered seven development candidates. She has over 17 years of experience in the pharmaceutical industry, has over 10 scientific publications and has presented at several international conferences.
Head of In vivo Pharmacology and Toxicology
Dr. Ines Glojnarić obtained her PhD in Medical biochemistry. For the last 20 years she has worked in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos holding several leading positions including Director of Pharmacology and Medicinal Safety, responsible for preclinical toxicity assessment, pharmacodynamics, pharmacokinetics and drug metabolism. During her career, she has worked on projects which have delivered seven development candidates, three of which have reached at least Phase I in the clinic. She has published 23 scientific publications and has presented at several international conferences. She has obtained several certificates in the field of pharmacology, good laboratory practice and management in pharmaceutical industry.
Director of Toxicology and LAS
Dr. Darko Marković holds a veterinary medicine degree, a master’s degree in veterinary medicine and a PhD in biomedicine and health/toxicology. He has obtained several certificates in various fields including toxicology, pharmacology, laboratory animal science (LAS) and GLP. He joined PLIVA in 1993, were he held several positions including Head of Toxicology and Director of LAS. During the time as a part of the GSK he spent a year at Parke Davis (USA). As part of his role within GSK, an Ethics Committee was established and the local Animal Facility was AAALAC I accredited. In 2010, within Galapagos, he was appointed to his current position with overall responsibility for toxicology, the animal facility and all LAS related work. He has twenty years’ experience in the pharmaceutical industry, over 20 scientific publications and has presented at several international conferences. As a lecturer he teaches at the University of Rijeka and Zagreb (toxicology and LAS).
Head of In vitro pharmacology
Martina Bosnar has a degree in molecular biology and a PhD in biology. Martina started her career in 2001 working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos where she has been advancing through positions of increasing responsibilities. Her work focused mainly on anti-inflammatory research. During her career she has contributed to progression of several drug discovery projects. She has authored over 15 scientific publications, has presented at several international conferences and is an inventor on 3 patents.
Director of Scale-up
Dr. Sulejman Alihodžić obtained his PhD in the field of chemistry. He conducted two years of postdoctoral research, awarded by the Robert A. Welch Postdoctoral Research Fellowship, at the University of North Texas. Sulejman started his career in 1998 working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos holding several leading positions including Head of Chemistry (GSK) and Director of Translational Chemistry (Galapagos) prior to taking his current position at the beginning of 2013. With 16 years of experience in the pharmaceutical industry, Sulejman is an expert in medicinal chemistry, especially in the areas of antibacterials, antimalarials and anti-inflammatory drugs. This is complemented by his extensive experience in scale-up and physico-chemical profiling of NCEs. During his career, he has worked on projects delivering five development candidates, published over 40 scientific papers and holds 15 granted patents and 10 patent applications.
Senior Research Fellow, Chemistry
Dr. Milan Mesić obtained his PhD degree in chemistry. His Postdoctoral research was at Wake Forest University, NC, USA, focused on the carcinogenicity of hydroxynitrosamines. Milan started his industry career 17 years ago working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos focused mainly on anti-inflammatory, cancer, CNS and cardiovascular projects assuming the lead chemist and project leader roles. During his career he has worked on projects which have delivered several preclinical candidates, one of which has reached Phase II. He has authorship on over 39 patents and on over 32 scientific publications and has presented at several international conferences.
Group Leader, CADD
Dr. Sanja Koštrun graduated in chemistry and obtained her PhD in the field of computational chemistry. She had several short-term post-doctoral positions at the University of Innsbruck, the University of Florida, Sussex University, and a one year post-doc Humbolt fellowship at the University of Marburg. Sanja has been working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos for the last 14 years. Throughout her industrial career, she has headed the Molecular modelling group and actively participated in a number of medicinal chemistry tasks and integrated projects mainly in the anti-infective and anti-inflammatory therapeutic areas, resulting in 29 published scientific papers.
Copyright © 2018 All Rights Reserved - Fidelta Ltd.